---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: Natural history, survival, and mortality"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: Natural history, survival, and mortality. Topics: Penetrance: lifetime risk of kidney failure with a high-risk genotype, Progression in established CKD: AASK and CRIC cohorts, Trajectory of eGFR decline in hypertension-attributed CKD, Real-world progression in genetically confirmed AMKD, and 11 further topics. 15 evidence topics quoted from 23 sources."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description/natural-history-survival-and-mortality"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: Natural history, survival, and mortality

<a id="heading-2.2.1.3"></a>

## 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

### Penetrance: lifetime risk of kidney failure with a high-risk genotype

> “Even among individuals with a high-risk genotype, having 2 APOL1 risk alleles does not necessarily lead to development of CKD. Approximately 15% of individuals with an APOL1 high-risk genotype will develop kidney failure, and a smaller fraction will develop FSGS.”
> “Despite the strong association between having a high-risk genotype and increased risk of kidney disease, it is not possible to predict which individuals with a high-risk genotype will develop CKD, idiopathic FSGS, hypertension-attributed kidney disease, HIV-1–associated nephropathy (HIVAN), or earlier failure of a kidney transplant from a donor with an APOL1 high-risk genotype.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

> “Individuals with a high-risk APOL1 genotype have been estimated to have a 15% to 30% lifetime risk of developing ESKD.”
> “The basis of this variable penetrance is currently unknown.”

Source: [Hopper and Olabisi (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11462457/)

> “Among individuals with high-risk APOL1 genotypes, the lifetime risk of developing kidney failure is ∼15%, indicating that other genetic variants or nongenetic modifiers likely contribute substantially to an individual patient’s risk of progressive kidney disease.”

Source: [da Silva Francisco et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11403072/)

<a id="topic-2.2.1.3-2"></a>

### Progression in established CKD: AASK and CRIC cohorts

> “In the AASK study, the primary outcome occurred in 58.1% of the patients in the APOL1 high-risk group and in 36.6% of those in the APOL1 low-risk group (hazard ratio in the high-risk group, 1.88; P<0.001). There was no interaction between APOL1 status and trial interventions or the presence of baseline proteinuria.”
> “Among the patients with diabetes, the eGFR slope (as measured in milliliters per minute per 1.73 m2 per year) was −1.5 among white patients, −2.7 among black patients in the APOL1 low-risk group, and −4.3 among black patients in the APOL1 high-risk group. Among the patients without diabetes, the corresponding eGFR slopes were −0.7, −1.0, and −2.9.”

Source: [Parsa et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3969022/)

<a id="topic-2.2.1.3-3"></a>

### Trajectory of eGFR decline in hypertension-attributed CKD

> “Over a median follow-up of 9 years, 24.0% of participants experienced steady eGFR decline, 25.9% had an unsteady decline, 25.6% were steady and stable, and 24.6% were unsteady but stable.”
> “The APOL1 high–risk group was associated with a greater odds for the steady decline pattern than the APOL1 low–risk group (unadjusted odds ratio, 2.45; 95% confidence interval, 1.62 to 3.69). This association remained significant after adjusting for demographic factors, baseline eGFR, urine protein-to-creatinine ratio, treatment assignment, and follow-up time (adjusted odds ratio, 1.59; 95% confidence interval, 1.00 to 2.52).”

Source: [Tin et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4974891/)

> “Individuals with the high-risk genotypes were 1.72-fold more likely to develop incident proteinuria compared with those with the low-risk genotypes (95% confidence interval, 1.27 to 2.32), independent of age, sex, ancestry, baseline eGFR, baseline systolic BP, and randomized treatment groups. Although eGFR declined faster after the onset of proteinuria, this rate did not differ significantly by APOL1 risk status.”

Source: [Chen et al. (2017b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5672963/)

<a id="topic-2.2.1.3-4"></a>

### Real-world progression in genetically confirmed AMKD

> “Almost half of patients in the US with APOL1-mediated kidney disease (AMKD) had progressed to stage 4 or 5 chronic kidney disease (CKD) by a mean age of 45.6 years”
> “In the pooled cohort with baseline eGFR below 90 mL/min/1.73 m2, the mean annual eGFR slope was –3.0 mL/min/1.73 m2 (95% CI, –3.3 to –2.7) in patients without diabetes and –4.2 mL/min/1.73 m2 (95% CI, –4.5 to –3.9) in patients with type 2 diabetes.”

Source: [AJMC (2026)](https://www.ajmc.com/view/real-world-amkd-data-highlight-quick-progression-unmet-needs)

<a id="topic-2.2.1.3-5"></a>

### Age at kidney failure and time to dialysis: company and laboratory statements

> “People with AMKD progress to end stage kidney disease at a faster rate than those with other forms of chronic kidney disease and reach kidney failure at a median age of 45 years old.”

Source: [Vertex Pharmaceuticals Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000056/vrtx-20251231.htm)

> “Compared with chronic kidney disease (CKD) patients of African ancestry with zero or one APOL1 risk variant, AMKD patients progress to dialysis nine to 12 years earlier and have a higher decline in the estimated glomerular filtration rate (eGFR).”

Source: [Labcorp](https://www.labcorp.com/tests/407154/apol1-genotyping)

<a id="topic-2.2.1.3-6"></a>

### FSGS: faster progression to kidney failure

> “FSGS associated with two APOL1 risk alleles associated with earlier age of onset (P = 0.01) and faster progression to ESRD (P < 0.01) but similar sensitivity to steroids compared with other subjects.”
> “The hazard ratio for progression was 2.3 (95% CI 1.43, 4), and median survival was 5 yr for subjects with 2 APOL1 risks alleles, compared with 13 yr for subjects with 0 or 1 APOL1 risk allele.”

Source: [Kopp et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3231787/)

> “APOL1 risk status is associated with lower kidney function, more glomerulosclerosis and interstitial fibrosis, and greater propensity to progress to ESRD.”

Source: [Kopp et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4446865/)

<a id="topic-2.2.1.3-7"></a>

### General population: incident CKD and kidney failure in ARIC

> “Carrying two risk alleles associated with a 1.49-fold increased risk of CKD (95% CI=1.02 to 2.17) and a 1.88-fold increased risk of ESRD (95% CI=1.20 to 2.93) compared with zero or one risk allele; associations persisted after adjusting for European ancestry. Among participants who developed CKD, those participants with two risk alleles were more likely to progress to ESRD than their counterparts with zero or one risk allele (HR=2.22, 95% CI=1.01 to 4.84).”

Source: [Foster et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3752955/)

> “Black race and APOL1 high-risk status were associated with faster eGFR decline (P<0.001 for each). However, we detected substantial overlap among the groups: median (10th–90th percentile) unadjusted eGFR decline was 1.5 (1.0–2.2) ml/min per 1.73 m2 per year for whites, 2.1 (1.4–3.1) ml/min per 1.73 m2 per year for blacks with APOL1 low-risk status, and 2.3 (1.5–3.5) ml/min per 1.73 m2 per year for blacks with APOL1 high-risk status.”

Source: [Grams et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5004654/)

<a id="topic-2.2.1.3-8"></a>

### Young adults: incident albuminuria and eGFR decline in CARDIA

> “The incidence rate per 1000 person-years (95% confidence interval) for albuminuria over 15 years was 15.6 (10.6–22.1) for high-risk blacks, 7.8 (6.4–9.4) for low-risk blacks, and 3.9 (3.1–4.8) for whites.”
> “After adjustment, high-risk blacks had a 0.45% faster yearly eGFRcys decline over 9.3 years compared with whites.”

Source: [Peralta et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4769203/)

<a id="topic-2.2.1.3-9"></a>

### Children with APOL1-associated glomerular disease

> “In the United States, children having a high-risk APOL1 genotype are reportedly at increased risk for early onset CKD.13,46 Findings suggest a common natural history for children with APOL1-associated glomerular disease, where children with high-risk genotypes have a more aggressive form of glomerular disease, which may relate to high rates of FSGS and prematurity.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

<a id="topic-2.2.1.3-10"></a>

### Prognostic heterogeneity among high-risk genotype carriers with preserved eGFR

> “APRS achieved a time-dependent area under the receiver operating characteristic curve (tAUC) of 86.5%, outperforming the Kidney Failure Risk Equation (66.1%) and polygenic risk scores, with 10-year event rates of 62.5% versus 3.3% across risk quintiles.”

Source: [Li et al. (2026a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13190321/)

<a id="topic-2.2.1.3-11"></a>

### COVID-19-associated collapsing glomerulopathy: short-term outcomes

> “At follow-up, 19 (86%) patients were alive, and 15 (68%) were dialysis free, including seven of 14 who initially required dialysis.”
> “Overall, 36% achieved partial remission of proteinuria, 32% had no remission, and 32% reached combined end points of ESKD or death.”

Source: [Kudose et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8806099/)

<a id="topic-2.2.1.3-12"></a>

### Mortality: death before kidney failure and all-cause mortality by genotype

> “Over a median follow-up of 9 years, 77 patients (11.1%) died before reaching the composite renal outcome, 204 (29.4%) received a diagnosis of end-stage renal disease, and 288 (41.6%) reached the composite renal outcome (Table 2). APOL1 status was not significantly associated with death before a diagnosis of end-stage renal disease.”

Source: [Parsa et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3969022/)

> “Over a mean follow-up of 5.1 years, APOL1 high-risk Blacks had a 2.67-fold higher risk for ESRD compared with low-risk Blacks (95% confidence interval [CI] = 1.05–6.79) in models adjusted for age and sex. This association was no longer significant upon further adjustment for baseline eGFRCrCys and albuminuria (hazard ratio [HR] = 1.08; 95% CI = .39–2.96). Rate of hospitalizations and risks of mortality and incident CKD did not differ significantly by APOL1 genotype status.”

Source: [Chen et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7855571/)

> “In a recessive genetic model adjusted for demographics, comorbidities, and kidney measures, there were no significant associations between APOL1 kidney-risk genotypes and death or the composite outcome of incident cardiovascular disease, which included coronary heart disease, stroke, myocardial infarction, and heart failure.”

Source: [Grams et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6779370/)

<a id="topic-2.2.1.3-13"></a>

### Kidney transplantation: allograft survival with kidneys from high-risk genotype donors

> “Twenty-two of 136 transplanted kidneys (16%) were from donors with two APOL1 nephropathy risk variants. Twenty five grafts failed; eight (32%) had two APOL1 risk variants.”
> “Kidneys from AA deceased donors harboring two APOL1 risk variants failed more rapidly after renal transplantation than those with zero or one risk variants.”

Source: [Reeves-Daniel et al. (2011)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3083491/)

> “Combined analysis of 1153 DDKTs from AA donors revealed donor APOL1 high-risk genotype (HR 2.05; p=3×10−4), older donor age (HR 1.18; p=0.05), and younger recipient age (HR 0.70; p=0.001) adversely impacted allograft survival.”
> “A competing risk analysis revealed that APOL1 impacted renal allograft survival, but not recipient survival.”

Source: [Freedman et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4684443/)

> “In the United States, living donors with APOL1 high-risk genotypes more often develop advanced CKD post donation,84 and receipt of deceased donor kidneys from APOL1 high-risk genotype donors are associated with more rapid graft failure.85–87 Results are mixed,88–90 but recipients with high-risk APOL1 genotypes may also have reduced graft survival.”

Source: [Ojo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13266834/)

<a id="topic-2.2.1.3-14"></a>

### Living kidney donors: kidney function after donation

> “Sixty-eight Black donors (15.3%) had APOL1 high-risk genotypes (G1/G1, G2/G2, or G1/G2). Home-based research study visits occurred a median (IQR) of 18.5 (16.9-20.5) years after donation.”
> “Black kidney donors with APOL1 high-risk genotypes had a higher risk of developing an eGFR of less than 45 mL/min/1.73 m2 than Black kidney donors without APOL1 high-risk genotypes (relative risk, 2.31; 95% CI, 1.16-4.61; P = .02) (after adjustment for predonation eGFR: relative risk, 1.91; 95% CI, 0.90-4.03; P = .09).”

Source: [Hsu et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42329639/)

> “At a median of 12 years after donation, donors with the APOL1 high-risk genotype had lower eGFR (57±18 versus 67±15 ml/min per 1.73 m2; P=0.02) and faster decline in eGFR after adjusting for predonation eGFR (1.19; 95% confidence interval, 0 to 2.3 versus 0.4; 95% confidence interval, 0.1 to 0.7 ml/min per 1.73 m2 per year, P=0.02). Two donors developed ESRD; both carried the APOL1 high-risk genotype.”

Source: [Doshi et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5875947/)

<a id="topic-2.2.1.3-15"></a>

### APOLLO: prospective study of transplant outcomes by donor and recipient genotype

> “The National Institutes of Health (NIH)–sponsored APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO) is prospectively assessing kidney allograft survival from donors with recent African ancestry based on donor and recipient APOL1 genotypes.”
> “The primary objective of APOLLO is determining whether the presence of APOL1 renal-risk genotypes in deceased-donors is associated with death-censored renal allograft survival.”
> “APOLLO aims to enroll all eligible kidney donors and kidney transplant recipients from U.S. transplant programs. This effort includes 260 academic and community-based programs with kidneys recovered from 58 OPOs (Figure 1).”

Source: [Freedman et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7056919/)

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
